The DOT1L inhibitor EPZ004777 downregulated ERα levels and markedly decreased tumor size after 3 weeks of treatment in hormone-positive and anti-estrogen-resistant breast cancer cells [229]. Here, ESR1 is linked to breast carcinoma.